The Skincubator is a wearable designed to enable immediate, prolonged skin-to-skin care for the tiniest preterm infants in ...

MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life ...

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of ...

GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian ...

IVDs are essential for disease detection, personalized treatment, and public health, driving growth in the global diagnostics ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

Some tout a daily semaglutide pill as a game-changer for weight-loss treatment. The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...

Developments shaping the medtech industry in 2025 offer a glimpse of what may unfold as we head into the new year.

The area of Dry Eye Syndrome is an illustrative example, with more than 340 million people affected globally, including about 40 million in the US – suffering from inflammation, nerve pain, light ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...